![]() |
市場調查報告書
商品編碼
1355848
葡萄糖生物感測器市場規模 - 按類型、技術、最終用途、全球預測,2032-2032 年Glucose Biosensors Market Size - By Type, By Technology, By End-Use, Global Forecast, 2032-2032 |
在生物感測器技術不斷創新的推動下,葡萄糖生物感測器市場規模預計從 2023 年到 2032 年將以超過 13% 的複合年成長率成長。
技術進步促進了更準確、更緊湊和方便用戶使用的葡萄糖生物感測器的發展,從而提高了葡萄糖測量的精度,並增強了使用者的便利性和舒適度。例如,2023 年6 月,總部位於聖地牙哥的Dexcom 透露,計畫在2024 年將新的葡萄糖感測技術產品推向美國市場。此外,持續的研發工作帶來了具有成本效益的生物感測器,從而提高了醫療保健提供者的採用率糖尿病患者將擴大市場前景。
整個葡萄糖生物感測器市場根據類型、技術、最終用途和地區進行分類。
就類型而言,由於全球患者對第 1 型糖尿病的認知不斷提高,持續血糖監測 (CGM) 領域的市場價值預計到 2032 年將獲得顯著成長。 2022 年,國際糖尿病聯盟報告稱,全球有 875 萬人患有第 1 型糖尿病。此外,CGM 技術的不斷進步帶來了更準確、方便用戶使用且更具成本效益的設備,從而促進了市場成長。
就最終用途而言,醫院領域的葡萄糖生物感測器產業規模將在 2022 年產生大量收入,預計 2023 年至 2032 年複合年成長率將達到 13.8%。這一成長是由於糖尿病及其併發症的盛行率不斷上升。根據 2021 年發表的研究,每年有近 25% 的第 1 型糖尿病患者和 30% 的第 2 型糖尿病患者入院治療。醫院環境對準確、即時血糖監測設備的需求也不斷增加,以便能夠及時介入並更好地控制血糖,最終改善患者的治療結果。
到2022 年,歐洲在全球葡萄糖生物感測器市場中佔據相當大的佔有率,並且由於醫療保健支出的成長和葡萄糖生物感測器技術的不斷進步,預計2023 年至2032 年期間將以顯著的複合年成長率成長。血糖監測設備的優惠報銷政策和知名市場參與者的強大存在也有助於市場擴張。此外,消費者可支配收入的增加以及先進產品的增加預計將推動區域市場的成長。例如,2023 年 9 月,美敦力 (Medtronic) 宣布其簡化版 Simplera CGM 獲得了 CE 標誌批准,為其在歐洲的推出做好了準備。
Glucose Biosensors Market size is projected to grow at over 13% CAGR from 2023 to 2032, driven by the ongoing innovations in biosensor technology.
Technological advancements have led to the development of more accurate, compact, and user-friendly glucose biosensors to offer improved precision of glucose measurements and enhanced convenience and comfort for users. For instance, in June 2023, San Diego-based Dexcom revealed plans to bring a new glucose-sensing technology product to the U.S. market by 2024. Furthermore, the ongoing R&D efforts resulting in cost-effective biosensors, leading to higher adoption among healthcare providers and individuals with diabetes will augment the market outlook.
The overall glucose biosensors market is categorized based on type, technology, end-use, and region.
With respect to type, the market value from the continuous glucose monitoring (CGM) segment is poised to gain significant traction through 2032 owing to the increasing patient awareness levels regarding diabetes type 1 worldwide. In 2022, the International Diabetes Federation reported that 8.75 million individuals across the globe have type 1 diabetes. Furthermore, the rising advancements in CGM technology have led to more accurate, user-friendly, and cost-effective devices, adding to the market growth.
In terms of end-use, the glucose biosensors industry size from the hospitals segment generated substantial revenue in 2022 and is forecasted to expand at 13.8% CAGR from 2023-2032. The growth is due to the rising prevalence of people suffering from diabetes and its complications. According to study published in 2021, nearly 25% of patients suffering from diabetes type 1 and 30% with diabetes type 2 are admitted to hospitals every year. The demand for accurate, real-time glucose monitoring devices in hospital settings is also on the rise for enabling timely interventions and better glycemic control for ultimately improving patient outcomes.
Europe held sizable share of the global glucose biosensors market in 2022 and is poised to grow at notable CAGR from 2023-2032 attributed to the growing healthcare expenditure and rising technological advancements in glucose biosensors. Favorable reimbursement policies for glucose monitoring devices and the strong presence of prominent market players are also contributing to the market expansion. Additionally, the rising disposable incomes of consumers coupled with the increasing availability of advanced products is projected to boost the regional market growth. For instance, in September 2023, Medtronic announced that its simplified Simplera CGM received the CE mark approval, setting it up for its introduction in Europe.